ScreenerHero

TARA Protara Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · protaratx.com
2.550USD-1.54%Mkt Cap: 153.06M $P/E: —

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigatio…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap153.06M USD
Enterprise Value11.24M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.44M USD
Revenue/Share—
Last Price2.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.51
PEG—
EV/EBITDA-0.15
EV/Revenue—
P/S—
P/B0.94
EPS (TTM)-1.32
EPS (Forward)-1.69
52W Range
2.5101% of range7.820
52W High7.820 USD
52W Low2.510 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-29.24%
ROA-27.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-56.37M USD
CapEx (TTM)94.00K USD
FCF Margin—
FCF Yield-26.45%
Net Debt-139.75M USD
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity0.02
Current Ratio10.97
Quick Ratio10.79
Book Value/Sh2.73 USD
Cash/Share2.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateJan 10, 2020
Splits
Last Split1:40
Split DateJan 10, 2020
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.71 USD
Upside (mean)+908.4%
Target Range20.00 USD – 30.00 USD
20.00+908.4% to mean30.00
# Analysts7
Ownership
Shares Out.59.10M
Float54.88M
Insiders2.30%
Institutions78.39%
Short Interest
Short Ratio11.2d
Short % Float7.60%
Short % Out.7.47%
Shares Short4.42M
Short (prev mo.)4.54M
Technical
SMA 503.748 (-32.0%)
SMA 2004.834 (-47.3%)
Beta1.47
S&P 52W Chg16.45%
Avg Vol (30d)1.21M
Avg Vol (10d)2.29M
Technical Indicators
RSI (14)18.2
MACD-0.3418
MACD Signal-0.2528
MACD Hist.-0.0890
BB Upper4.334 USD
BB Middle3.354 USD
BB Lower2.373 USD
BB Width58.47%
ATR (14)0.2083 USD
Vol Ratio (20d)0.45x